ALI HEALTH (00241) experienced a sharp decline, initially dropping more than 6%, though the loss has since narrowed significantly. At the time of writing, the stock is down 3.08%, trading at HK$4.4 with a turnover of HK$471 million.

The company reported its full-year results for the period ending March 31, 2026. Total revenue reached approximately RMB 34.255 billion, representing a year-on-year increase of 12.0%. Net profit amounted to about RMB 1.9363 billion, up 35.2% compared to the previous year. Adjusted net profit was RMB 2.3262 billion, marking a 19.3% increase, with the adjusted net profit margin improving from 6.4% to 6.8%.

A final dividend of 5.95 cents per share and a special dividend of 13.52 cents per ordinary share have been proposed.

Additionally, ALI HEALTH announced on the same day that Chief Financial Officer Tu Yanwu has tendered his resignation as an executive director and CFO. The company has appointed Ms. Sheng Mengyue as the new executive director and Chief Financial Officer.

ALI HEALTH stated that Tu Yanwu resigned to dedicate more time to personal affairs and development, with the resignation effective at the close of business on May 15, 2026. Tu Yanwu has confirmed that there are no disagreements between him and the board.